Cargando…

Attenuated Expression of Apoptosis Stimulating Protein of p53-2 (ASPP2) in Human Acute Leukemia Is Associated with Therapy Failure

Inactivation of the p53 pathway is a universal event in human cancers and promotes tumorigenesis and resistance to chemotherapy. Inactivating p53 mutations are uncommon in non-complex karyotype leukemias, thus the p53-pathway must be inactivated by other mechanisms. The Apoptosis Stimulating Protein...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schittenhelm, Marcus M., Illing, Barbara, Ahmut, Figen, Rasp, Katharina Henriette, Blumenstock, Gunnar, Döhner, Konstanze, Lopez, Charles D., Kampa-Schittenhelm, Kerstin M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842400/ https://www.ncbi.nlm.nih.gov/pubmed/24312201 http://dx.doi.org/10.1371/journal.pone.0080193

Ejemplares similares

Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Alternative splicing of the tumor suppressor ASPP2 results in a stress-inducible, oncogenic isoform prevalent in acute leukemia
por: Schittenhelm, Marcus Matthias, et al.
Publicado: (2019)

Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoforms
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2013)

Alternative splicing of Apoptosis Stimulating Protein of TP53-2 (ASPP2) results in an oncogenic isoform promoting migration and therapy resistance in soft tissue sarcoma (STS)
por: Tsintari, Vasileia, et al.
Publicado: (2022)

Crenolanib is a type I tyrosine kinase inhibitor that inhibits mutant KIT D816 isoforms prevalent in systemic mastocytosis and core binding factor leukemia
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2017)

ASPP2κ Is Expressed In Human Colorectal Carcinoma And Promotes Chemotherapy Resistance And Tumorigenesis
por: Rieger, Ingmar, et al.
Publicado: (2021)

Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns
por: Kampa-Schittenhelm, Kerstin Maria, et al.
Publicado: (2016)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
por: Kliebhan, Johannes, et al.
Publicado: (2022)

Epigenetic activation of O-linked β-N-acetylglucosamine transferase overrides the differentiation blockage in acute leukemia
por: Kampa-Schittenhelm, K.M., et al.
Publicado: (2020)

Dasatinib overrides the differentiation blockage in a patient with mutant-KIT D816V positive CBFβ-MYH11 leukemia
por: Kampa-Schittenhelm, Kerstin M., et al.
Publicado: (2018)

Molecular interactions of ASPP1 and ASPP2 with the p53 protein family and the apoptotic promoters PUMA and Bax
por: Patel, Seema, et al.
Publicado: (2008)

ASPP1 and ASPP2 bind active RAS, potentiate RAS signalling and enhance p53 activity in cancer cells
por: Wang, Y, et al.
Publicado: (2013)

Regulation of immunological tolerance by the p53-inhibitor iASPP
por: Akama-Garren, Elliot H., et al.
Publicado: (2023)

Regulation of ASPP2 Interaction with p53 Core Domain by an Intramolecular Autoinhibitory Mechanism
por: Rotem-Bamberger, Shahar, et al.
Publicado: (2013)

FHL2 interacts with iASPP and impacts the biological functions of leukemia cells
por: Lu, Wenting, et al.
Publicado: (2017)

Clinical implications of subclonal TP53 mutations in acute myeloid leukemia
por: Prochazka, Katharina T., et al.
Publicado: (2019)

Functional Classification of TP53 Mutations in Acute Myeloid Leukemia
por: Dutta, Sayantanee, et al.
Publicado: (2020)

Nuclear EGFR impairs ASPP2-p53 complex-induced apoptosis by inducing SOS1 expression in hepatocellular carcinoma
por: Liu, Kai, et al.
Publicado: (2015)

ASPP2 promotes cell apoptosis in cervical cancer through inhibiting autophagy
por: Jiang, Feiyun, et al.
Publicado: (2022)

Inhibitor of Apoptosis-Stimulating Protein of p53 (iASPP) Is Required for Neuronal Survival after Axonal Injury
por: Wilson, Ariel M., et al.
Publicado: (2014)

Nucleostemin and ASPP2 expression is correlated with pituitary adenoma proliferation
por: MA, LIN, et al.
Publicado: (2013)

ASPP2 Is a Novel Pan-Ras Nanocluster Scaffold
por: Posada, Itziar M. D., et al.
Publicado: (2016)

p53 inhibitor iASPP is an unexpected suppressor of KRAS and inflammation-driven pancreatic cancer
por: Miller, Paul, et al.
Publicado: (2023)

ASPP2 involvement in p53-mediated HIV-1 envelope glycoprotein gp120 neurotoxicity in mice cerebrocortical neurons
por: Liu, Zhiying, et al.
Publicado: (2016)

Downregulation of Inhibition of Apoptosis-Stimulating Protein of p53 (iASPP) Suppresses Cisplatin-Resistant Gastric Carcinoma In Vitro
por: Yu, Jianyong, et al.
Publicado: (2017)

Structural Basis for ASPP2 Recognition by the Tumor Suppressor p73
por: Canning, Peter, et al.
Publicado: (2012)

ASPP2 enhances Oxaliplatin (L-OHP)-induced colorectal cancer cell apoptosis in a p53-independent manner by inhibiting cell autophagy
por: Shi, Ying, et al.
Publicado: (2015)

Caspase cleavage of iASPP potentiates its ability to inhibit p53 and NF-κB
por: Hu, Ying, et al.
Publicado: (2015)

Interdependent Nuclear Co-Trafficking of ASPP1 and p53 Aggravates Cardiac Ischemia/Reperfusion Injury
por: Yang, Ying, et al.
Publicado: (2022)

Exogenous p53 and ASPP2 expression enhances rAdV-TK/GCV-induced death in hepatocellular carcinoma cells lacking functional p53
por: Liu, Xiuhong, et al.
Publicado: (2016)

ASPP2 inhibits hepatitis B virus replication by preventing nucleus translocation of HSF1 and attenuating the transactivation of ATG7
por: Wang, Shanshan, et al.
Publicado: (2021)

CDK1 interacts with iASPP to regulate colorectal cancer cell proliferation through p53 pathway
por: Gan, Wei, et al.
Publicado: (2017)

iASPP mediates p53 selectivity through a modular mechanism fine-tuning DNA recognition
por: Chen, Shuo, et al.
Publicado: (2019)

Nuclear iASPP determines cell fate by selectively inhibiting either p53 or NF-κB
por: Ge, Wenjie, et al.
Publicado: (2021)

ASPP2 inhibits tumor growth by repressing the mevalonate pathway in hepatocellular carcinoma
por: Liang, Beibei, et al.
Publicado: (2019)

ASPP2 maintains the integrity of mechanically stressed pseudostratified epithelia during morphogenesis
por: Royer, Christophe, et al.
Publicado: (2022)

ASPP2 Plays a Dual Role in gp120-Induced Autophagy and Apoptosis of Neuroblastoma Cells
por: Liu, Zhiying, et al.
Publicado: (2017)

Blocking iASPP/Nrf2/M-CSF axis improves anti-cancer effect of chemotherapy-induced senescence by attenuating M2 polarization
por: Liu, Hao, et al.
Publicado: (2022)

Sertad1 antagonizes iASPP function by hindering its entrance into nuclei to interact with P53 in leukemic cells
por: Qiu, Shaowei, et al.
Publicado: (2017)

Reactivating p53 functions by suppressing its novel inhibitor iASPP: a potential therapeutic opportunity in p53 wild-type tumors
por: Dong, Peixin, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vp23s4chh06hm96809s6dii519